FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| The Effect of the Second Forward View on the Detection Rate of Sessile Serrated Lesions in the Proximal Colon: A Single-Center Prospective Randomized Controlled Study. PMID 39688959 · Clin Transl Gastroenterol · 2025-Feb-01 Study is a randomized trial in oncology (colorectal cancer screening) but does not meet eligibility criteria: it is not a Phase III drug trial and has no time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma. PMID 39660637 · Rhinology · 2025-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial. PMID 39602139 · JAMA Dermatol · 2025-Feb-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Patient Profiles in Randomized Controlled Trials Versus a Real-World Study in Psoriatic Arthritis: Scoping Review and Metaanalysis. PMID 39547694 · J Rheumatol · 2025-Feb-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Automated patient selection and care coaches to increase advance care planning for patients with cancer. PMID 39348179 · J Natl Cancer Inst · 2025-Feb-01 The study is a cluster-randomized, stepped-wedge trial in oncology patients, but it is not a drug trial, does not report Phase III/IIIb or Phase II/III status, and its primary endpoint is a process measure (proportion of visits with prognosis documentation), not a time-to-event efficacy endpoint like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| An Exploratory Analysis of the Conditional Neurocognitive Function Failure Risk in Patients Receiving Whole Brain Radiation Therapy for Brain Metastases on NRG Oncology CC001. PMID 39332644 · Int J Radiat Oncol Biol Phys · 2025-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. PMID 39332395 · JAMA Cardiol · 2025-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The risk of treatment-related toxicities with PD-1/PD-L1 inhibitors in patients with lung cancer. PMID 39319530 · Int J Cancer · 2025-Feb-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial. PMID 39299550 · Int J Radiat Oncol Biol Phys · 2025-Feb-01 The record meets criteria for oncology, human, randomized, Phase 3, and time-to-event endpoints with original results. However, the drug intervention is not clearly established as a systemic drug therapy in the context of a Kaplan-Meier digitization cohort for drug-containing interventions. The intervention is a combination of a procedural technique (TACE) and radiation therapy (EBRT), which does not satisfy the requirement for a drug-containing intervention as defined by the adjudication rules. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Evaluating the Impact of Post-Esophagectomy Exercise on 2- and 5-Yr Survival: Findings from the PERFECT Trial. PMID 39293388 · Med Sci Sports Exerc · 2025-Feb-01 The record reports an original randomized trial with time-to-event endpoints in oncology, but the intervention is exercise-based, not drug-containing. Additionally, the trial phase is not established as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled Trial. PMID 39270828 · Int J Radiat Oncol Biol Phys · 2025-Feb-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls. PMID 39140490 · Am J Gastroenterol · 2025-Feb-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Randomized, Double-Blind, Active-Controlled Phase 3 Study to Evaluate Efficacy and Safety of Zastaprazan Compared With Esomeprazole in Erosive Esophagitis. PMID 38976448 · Am J Gastroenterol · 2025-Feb-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. PMID 38899967 · Hepatology · 2025-Feb-01 This is a prospective biomarker cohort study comparing diagnostic performance of HES V2.0, GALAD, and ASAP scores for HCC detection. It is not a randomized controlled trial. The primary endpoints are diagnostic accuracy metrics (sensitivity/TPR, AUROC), not time-to-event efficacy outcomes (OS, PFS, DFS, etc.). No drug intervention is described; the study evaluates diagnostic scores. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Concizumab prophylaxis in people with hemophilia A or B without inhibitors: patient-reported outcome results from the phase 3 explorer8 study. PMID 40166710 · Res Pract Thromb Haemost · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating Scale. PMID 40018746 · Clin Exp Rheumatol · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2. PMID 39992021 · J Cachexia Sarcopenia Muscle · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics. PMID 39983682 · Emerg Infect Dis · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials. PMID 39982105 · Cephalalgia · 2025-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis. PMID 39980062 · Clin Transl Sci · 2025-Feb The study is a Phase III randomized trial of imetelstat in oncology, but the reported endpoint is a cardiac safety biomarker (QTcF prolongation) for proarrhythmic risk assessment. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or hazard ratio analysis. Therefore, it is excluded from the Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial. PMID 39979665 · Nat Cancer · 2025-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in CTEPH: Insights From the RACE Trial. PMID 39965044 · Circ Cardiovasc Interv · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC. PMID 39957151 · Future Oncol · 2025-Feb The publication is a clinical trial protocol for an ongoing phase III randomized study in oncology with a drug intervention. It describes the study design but does not present results or data, so time-to-event efficacy endpoints (e.g., OS, PFS) cannot be assessed from the abstract. It is excluded as a protocol without results. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| The effect of the fenugreek hydrolyzed protein on lipid profile in patients with mild-to-moderate hypercholesterolemia: A confirmatory triple-blind randomized-controlled clinical trial. PMID 39935620 · Phytomed Plus · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Correction to "Nivolumab Plus Chemotherapy or Ipilimumab Versus Chemotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma (CheckMate 648): 29-Month Follow-Up From a Randomized, Open-Label, Phase III Trial". PMID 39927664 · Cancer Med · 2025-Feb The record is for a published erratum to a Phase III trial abstract, but the abstract content is missing. While the title indicates a 29-month follow-up from a randomized, open-label, Phase III trial (CheckMate 648) in esophageal squamous cell carcinoma with a drug-containing intervention, the absence of the abstract prevents confirmation of a time-to-event efficacy endpoint (e.g., OS, PFS, HR, Kaplan-Meier) and whether this is an original result report. The publication type is an erratum, which is not a primary research report. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide. PMID 39921387 · Genes Chromosomes Cancer · 2025-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Pharmacodynamics of the S1P1 receptor modulator cenerimod in a phase 2b randomised clinical trial in patients with moderate to severe SLE. PMID 39919901 · Ann Rheum Dis · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial. PMID 39919893 · Ann Rheum Dis · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials. PMID 39914429 · Lancet Oncol · 2025-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM. PMID 39909647 · JACC Heart Fail · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction: A Patient-Level Analysis of DAPA-HF and DELIVER. PMID 39909641 · JACC Heart Fail · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study. PMID 39908699 · ESMO Open · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Transarterial Chemoembolization with Radiofrequency Ablation versus Surgical Resection for Small Late-Recurrence Hepatocellular Carcinoma. PMID 39903071 · Radiology · 2025-Feb The record describes a randomized, controlled trial in human oncology (HCC) with a primary OS endpoint and Kaplan-Meier analysis. However, it compares two non-drug interventions (TACE-RFA vs. SR). TACE is a procedure, and the intervention is not a systemic or investigational drug as defined by the criteria. Therefore, it is excluded as a non-drug-only trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| First-line chemotherapy with selective internal radiation therapy for intrahepatic cholangiocarcinoma: The French ACABi GERCOR PRONOBIL cohort. PMID 39897613 · JHEP Rep · 2025-Feb The study is an observational cohort analysis, not a randomized controlled trial. While it reports Phase III-like results with time-to-event endpoints and drug intervention, the non-randomized design and lack of explicit Phase III/IIIb or Phase II/III trial classification exclude it. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Coping, Emotional Processing, and Cancer-Related Symptoms in Breast Cancer Survivors: Cross-Sectional Secondary Analysis of the REPAT Study. PMID 39891317 · Psychooncology · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years: results of the long-term extension of the DoRIS randomised trial. PMID 39890232 · Lancet Glob Health · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| SELective defunctioning Stoma Approach in low anterior resection for rectal cancer (SELSA): Protocol for a prospective study with a nested randomized clinical trial investigating stoma-free survival without major LARS following total mesorectal excision. PMID 39887540 · Colorectal Dis · 2025-Feb 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| It is Time to Address Fear of Cancer Recurrence in Family Caregivers: Feasibility and Acceptability of a Randomized Pilot Study of the Family Caregiver Version of the Fear of Recurrence Therapy (FC-FORT). PMID 39887474 · Psychooncology · 2025-Feb This is a pilot/feasibility study of a psychosocial intervention (therapy) for family caregivers of cancer patients. It is not a Phase II/III or Phase III/IIIb randomized trial. It does not involve a drug intervention. The primary endpoints are feasibility and acceptability, not time-to-event efficacy endpoints like OS or PFS. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of tamoxifen in non-ambulant patients with Duchenne muscular dystrophy: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (TAMDMD Group B). PMID 39879732 · Neuromuscul Disord · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trial. PMID 39874991 · J Infect · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial. PMID 39874903 · ESMO Open · 2025-Feb The record is a Phase IIIb oncology trial with drug intervention and time-to-event endpoints, but it is not randomized, which is a required criterion for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Immune checkpoint inhibitors plus taxane-based chemotherapy for patients with advanced/metastatic NSCLC: a systematic review and meta-analysis across different PD-L1 expression levels. PMID 39874440 · Expert Rev Anticancer Ther · 2025-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Assessment of Reperfusion Efficacy of Altelyse Versus Actilyse in Patients with Acute Myocardial Infarction: A Phase 3, Randomized, Double-Blinded, Non-inferiority Clinical Trial. PMID 39873854 · Clin Drug Investig · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Single-center off-label benralizumab use for refractory hypereosinophilic syndrome demonstrates satisfactory safety and efficacy. PMID 39866927 · EJHaem · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. PMID 39862880 · Lancet Neurol · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. PMID 39862879 · Lancet Neurol · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study. PMID 39855251 · Lancet Oncol · 2025-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial. PMID 39848272 · Lancet Oncol · 2025-Feb Eligible on oncology, human, randomized, Phase III, time-to-event endpoint, and original result. Excluded because the intervention (thermal ablation vs. surgical resection) is a procedure/device and does not meet the requirement for a drug-containing intervention. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy. PMID 39847856 · Mult Scler Relat Disord · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. PMID 39838118 · Nat Med · 2025-Feb The trial meets criteria for oncology, human, randomized, Phase III, and drug intervention, and reports original results. However, the primary endpoint is pCR, which is not a time-to-event efficacy endpoint as defined (OS, PFS, DFS, EFS, RFS, TTP, or any endpoint analyzed with Kaplan-Meier or HR). Therefore, it is ineligible for this digitization cohort. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |